PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) is one of 284 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare PharmaCyte Biotech to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends. Risk and Volatility […]
Equitec Proprietary Markets LLC cut its holdings in shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Free Report) by 81.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,415 shares of the company’s stock after selling 269,279 shares during the quarter. […]
PharmaCyte Biotech, Inc. (OTCMKTS:PMCB – Get Rating) shares traded up 1% during mid-day trading on Monday . The stock traded as high as $2.97 and last traded at $2.96. 17,870 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 66,974 shares. The stock had previously closed at $2.93. […]
PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of -$0.27–$0.27 for the period, compared to the consensus estimate of -$0.24. The company issued revenue guidance of -. OTCMKTS PMCB opened at $2.47 on Thursday. PharmaCyte Biotech has a 1 year low […]
PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations […]